**[미래에셋 제약/바이오 김승민]**
**9/28 Daily**

[https://t.me/bioksm](https://t.me/bioksm)


 **글로벌 바이오/제약**
────────────────────
 [FDA, AbbVie의 파킨슨병 치료제 Juvmo(tavapadon) 승인](https://news.google.com/rss/articles/CBMiuwFBVV95cUxNNXM3VVNjc3JYVmVLRGkxTXJrakVrdjlFRG80R2hQWHNZZkFqR1FVZjhldVVCalJOempscGY5OXlUa1dDTnQ0TG9zVi1ZMzJZUXVJb2VfM0ROYk9OeHNrNTJ3ejdsN2lhQ3VmZjNlU0p2ZG40VjdxMC0wZ2E3UWhPS2Ixa2sweE5uMFVrZXpmOFdEbXpGY3UwNlBxQ25Kam1HWkJPTUkteFUzSWJmWVhFelB3RzNjVUlQR004?oc=5)

 [FDA, Mirum의 초희귀 연조직질환 치료제 Atebrioz(zilurgisertib) 승인](https://news.google.com/rss/articles/CBMiugFBVV95cUxNTnRScXF6U1QyYm9qejFheHhZajVzb2dIZTRhcjJLV0R2TGJ5bUZpQU84Sm9JRkEyN2VzWFNlS2R3SExtN2cwTk9ZeDZ2ZEtYSGNIaWpndDRGY09IQ2JqY21Ia2kzbmp1djRyMVlBZHFvaEVOY0VlSGdhQmFVLURBcGMxdk1qaUVSOENxb2dKcFhleHRQcnBtN1ZRQmlBOVcyZktIZC1RQmVGWGRZZ3FJekg2anNEYmVmMGc?oc=5)

 [FDA, Lilly의 Olumiant(baricitinib) 12세 이상 소아 중증 원형탈모증 적응증 승인](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-olumiant-baricitinib-pediatric-patients-12)

 [FDA, Elevar의 담관암2차 치료제 Lyrfigtu(lirafugratinib) 승인](https://endpoints.news/elevar-wins-first-fda-approval-with-second-line-bile-duct-cancer-drug/)

 [Merck·Daiichi, 공동 개발 B7-H3 ADC(I-DXd) 미국 허가 신청 철회](https://news.google.com/rss/articles/CBMitAFBVV95cUxPY255UmdNQXFqU296Vi13YzlWX3Rnei1KX1NNZGQybU1hUVJUeUxxUU9oa0dvWk0zTzZXRk5xS01kVGhXWG1Ca000VVlZUlpJdVA1c1N2WEJCU1BGM3huRjlCZHZkQzEzdUdQLTZZS1Zka0ZRNi1Ya1lmekQ4M1Vnd2xOWTRUSldYdzZDMnFlQzc3dXdlWWV0WHJiNUZSUjZ0RDhXWFJfY3Q4TjhxVU8zczZGVHc?oc=5)

 [Erendil Labs, Genentech와 15억 달러 규모 이중특이항체 계약 체결](https://news.google.com/rss/articles/CBMipgFBVV95cUxNWFhYam9tUHVsNmtGR3Q1YlY0NGlRSDY1M2k2bWNmcUQ3QVNfeHFtX1JkZmo4b29ValFTQ3ZvQWo5WFQydFZoRkl4WWwzcDZMR0ZJTGJCSHA5RndrQVh5TENSdXFPTzU4eUZzcGVfRVJYbVlmMDk2REdDWF81SzVMY1ZtMlg2blFkbmZiMDVkWUpYbXpWcmtCRzBpN0dvamhneU9GVHNn?oc=5)

 [Nanexa, Novo Nordisk와 11억 7천만 유로 서방향 장기지속 기술 계약 체결](https://news.google.com/rss/articles/CBMiwwFBVV95cUxQYjdmc2U3RUlBUTA2U0dJRTJPZUdHeEhnLW0wekM5b2xqamJzS2dTbzV1ZlFVNzJ6THlXdzdMVVlKMXRRWXJ6cWJIcG94OVQzY0ZRTFlfWWlKdG5GMVZkbGZEcURpamxrdklBNjdDdDYwdmp0QWx0YTRHcmhMYmdlcjJmU0IyUFlvdmRZNjlvQVFXaGUwLWc3Z0o4NlVGU0dQRjFudFF0Wkduekw2MW15STljb1RrZ2ZwQkhiVUZjckZJQ2c?oc=5)

 [J&J의 Carvykti, 다발성골수종에서 '완치 가능성' 입증하는 5년 임상데이터 발표](https://news.google.com/rss/articles/CBMiU0FVX3lxTE51WW5lS05IVUZWT0JLamI0bmZMOExpdzl3bU1qM3R6RkJSbjVodkQxbXp5MDNaV3JGVGVaczdnaVZDbldNcElhUDU1VklxN081UGlz?oc=5)

 [J&J의 TREMFYA, 축성 건선관절염 임상에서 척추통증 및 경직 개선 첫 입증 - IL-23 억제제 유일](https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-show-significant-improvement-in-spinal-pain-and-stiffness-in-landmark-axial-psoriatic-arthritis-psa-study)

 [Evommune은 EADV 2026에서 아토피 치료제 EVO301 2a상 임상에 대한 후기 발표를 진행할 예정](https://firstwordpharma.com/story/8082771)


 **한국 바이오/제약**
────────────────────
 [‘3전4기’ 진양곤 HLB그룹 의장, 세 번 고배 끝에 美 FDA 신약 품다](https://news.google.com/rss/articles/CBMibkFVX3lxTFBxNE9OamdXbE1YTXI1T1RLTEtfZ3JyRENqWHc0TndrRDBPRF9PaVpNaV91X2h4bVdSLWoyd0RaMmt6a21uOUw2RkNJaDBVR3BsYUExRkNDdG9UbEhIaGFKMEtiMGNnVmM1LUpVeHpB?oc=5)

 [미국, 한국산 세포·유전자치료제 등 관세 0% 적용](https://www.hitnews.co.kr/news/articleView.html?idxno=79406)

 [오름테라퓨틱, BMS 중단에도 “ORM-1153 임상 예정대로”](https://dealsite.co.kr/articles/169614)

 [큐리언트 "이중 페이로드 ADC, 조만간 글로벌 사업화 성과 기대"](https://news.google.com/rss/articles/CBMiWkFVX3lxTFBNbE94LVNBR3lLUk5KdnZXM0pxZXR6clVFOVpGQ0oxazBaR0RVLUxJOXhSNndQcld2ZnRXT0d0NUExZEFueTNQclZjWVlSVDBvb25nYVhFQWdhdw?oc=5)

 [‘약국 2만4000곳 품은’ 바로팜, 11월 상장 추진](https://news.google.com/rss/articles/CBMiWkFVX3lxTE42bmFnUG5KZl9PR3NBUWt4eUxvS3d1WUpOeExDZjZ6MG1NYVM3ejV1VlJvV3dBZVoyQTU4eDJVVDg4am5veDR4Sy1PRHdDdkVMUTZUbENGdzVKZw?oc=5)


────────────────────